NTLA

Intellia Therapeutics, Inc.

Halal Rating :
Comfortable
Last Price $12.20 Last updated:
Market Cap $2.28b
7D Change -5.43%
1 Year Change -59.6%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • In Vitro
  • In Vivo Diagnostic Substances
Exchange NASDAQ
Next Earnings Date Nov. 11, 2024

Intellia Therapeutics is a biotechnology company focused on developing curative genome editing treatments using CRISPR/Cas9 technology. The company aims to develop therapies for genetic diseases and cancers through either ex vivo or in vivo approaches. Their pipeline includes treatments for transthyretin amyloidosis, hereditary angioedema, and various oncology applications.

The company is primarily in the research and development phase, with most of its programs in clinical trials. Revenue currently comes mainly from collaboration agreements and research partnerships with other pharmaceutical companies.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $9.11m $153.88m - - 0.00% 0.00%
June 30, 2024 $6.96m $146.0m - - 0.00% 0.00%
March 31, 2024 $28.93m $142.94m - - 0.00% 0.00%

Company Impact

Help us evaluate Intellia Therapeutics, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates